Reconstruction of the alveolar–capillary barrier in vitro based on a photo‐responsive stretchable Janus membrane

share:

Brief intro:

  • Author: Changmin Shao, Ting Cao, Xiaochen Wang, Qihui Fan, Fangfu Ye
  • Journal: Smart Medicine
  • Publication Date: 2023 Feb 21

Products/Services used in the paper

Request Quote

Abstract

The lung is the respiratory organ of the human body, and the alveoli are the most basic functional units of the lung. Herein, a photo‐responsive stretchable Janus membrane was proposed for the reconstruction of the alveolar–capillary barrier in vitro. This Janus membrane was fabricated by photocrosslinking methylacrylamide gelatin (Gelma) hydrogel and N‐isoacrylamide (NIPAM) hydrogel mixed with graphene oxide (GO). The Gelma hydrogel containing large amounts of collagen provides a natural extracellular matrix environment for cell growth, while the temperature‐sensitive NIPAM hydrogel combined with GO gives the membrane a light‐controlled stretching property. Based on this Janus membrane, an open polydimethylsiloxane chip was established to?coculture alveolar epithelial cells and vascular endothelial cells at the air–liquid interface. It was demonstrated that the alveolar epithelial cells cultured on the upper side of the Janus membrane could express epithelial cell marker protein E‐cadherin and secrete alveolar surfactant. In addition, VE‐cadherin, an endothelium‐specific protein located at the junction between endothelial cells, was also detected in vascular endothelial cells cultured on the underside of Janus membrane. The constructed lung tissue model with the dynamically stretchable Janus membrane is well‐suited for COVID‐19 infection studies and drug testing.

Keywords: alveolar–capillary barrier, in vitro lung models, lung‐on‐a‐chip, photo‐responsive material, stretchable Janus membrane

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download